|
Targeting CD44-Moesin Interactions with Small Molecules for Alzheimer’s Disease
This technology is a small molecule compound that could serve as a potential therapeutic for Alzheimer’s Disease (AD). The compound binds to Moesin, a protein that is associated with AD. It targets interactions between Moesin and CD44, an antigen that also has been shown to be a biomarker for AD. Targeting CD44 and Moesin interactions has proved...
Published: 4/3/2023
|
Inventor(s): May Khanna, Judith Tello Vega, Haley Williams, Vijay Gokhale, Marcel Patek, Jake Carlson
Keywords(s):
Category(s): Technology Classifications > Life Sciences
|
|
Small Molecules Targeting Protein-RNA Interactions in ALS and Related Neurodegenerative Diseases
This invention is an in silico molecule capable of mitigating locomotor dysfunctions through TDP-43 contained RNA remodeling.
Background:
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects the function of nerves and muscles. In the United States over 6,000 people are diagnosed each year with an estimated 15 cases diagnosed...
Published: 4/3/2023
|
Inventor(s): Daniela Zarnescu, May Khanna, Vijay Gokhale
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Allosteric Modulators of TDP-43 for Treating Neurodegenerative Diseases
This invention is a small molecule drug, nTRD22, that can be used to treat currently incurable neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and potentially even Alzheimer’s disease (AD) and Parkinson’s disease (PD). This molecule targets the N-terminal domain (NTD) of the DNA binding...
Published: 4/3/2023
|
Inventor(s): May Khanna, Liberty Francois-Moutal, Niloufar Mollasalehi, Vijay Gokhale, David Scott, Judith Tello Vega, Haley Williams
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences
|
|
New Strategies to Block RIPK1/3/MLKL-Mediated Neurodegeneration
University of Arizona researchers have discovered several small molecules that represent a new class of RIPK1/3 targeting therapeutics that can potentially be used in the treatment of Alzheimer’s Disease. These molecules inhibit necroptosis, which is a cell death pathway related to neurodegenerative diseases. Necroptosis is form of cell death...
Published: 4/3/2023
|
Inventor(s): May Khanna, Jonathan Sanchez, Vijay Gokhale, Salvatore Oddo
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules
|
|
G-Quadruplex Targeting Small Molecules for the Treatment of Castration Resistant Prostate Cancer and HSV-1
This technology consists of a new class of small-molecules that target G-quadruplex formation. These compounds have the potential to treat a wide variety of diseases including prostate cancer. In particular, these compounds are aimed at helping individuals who have developed a resistance to androgen-deprivation therapies (ADT). While most ADT therapeutics...
Published: 11/16/2023
|
Inventor(s): Elsa Reyes Reyes, Cynthia Miranti, Laurence Hurley, Vijay Gokhale, Kui Wu, Sara Richter
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics
|
|
Design and Synthesis of a New Class of G-Quadruplex-Binding Ligands for the Treatment of Cancer and Other Diseases
c-Myc is an essential transcription factor that plays an important role in cell proliferation, differentiation, as well as maintenance of other cell-cycle functions. Under pathologic conditions, c-Myc expression is highly elevated, contributing to development of malignancy in majority of human cancers. Thus researchers have been looking for compounds...
Published: 11/16/2023
|
Inventor(s): Laurence Hurley, Vijay Gokhale, Srinivasa Reddy Kota, Seongmin Hahn
Keywords(s): anticancer activity, G-quadruplex, quindolines
Category(s): Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Therapeutics
|
|
Novel Inhibitors of the Androgen Receptor for the Treatment of Castration Resistant Prostate Cancer (CRPC)
This invention is a new class of heterocyclic small-molecules designed to antagonize the androgen receptor. These molecules have promising biological activity in a prostate specific cell line.
Background:
The primary method for treating early stage prostate cancer is via androgen deprivation therapy because prostate cancer needs androgen in order...
Published: 11/16/2023
|
Inventor(s): Christopher Hulme, Yeng Jeng Shaw, Vijay Gokhale
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
|
Design and Synthesis of a New Class of G-Quadruplex Binding Ligands for the Treatment of Cancer
This technology identifies new chemical entities (NCEs) that, according to FRET assay, target the G-quadruplex secondary DNA structure. The disclosed NCEs possess structural features with side chains that may improve potency with specificity over previously reported c-Myc suppressors. The Hurley lab previously discovered that stabilization of a specific...
Published: 11/16/2023
|
Inventor(s): Laurence Hurley, Biswanath De, Venkateshwar Chappeta, Tracy Brooks, Vijay Gokhale, Cristina Beman, Heather Perry
Keywords(s):
Category(s): Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Therapeutics
|
